Active DNA Aβ42 vaccination as immunotherapy for Alzheimer disease

Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease

(2012) Martin Farlow et al.   Alzheimers & Dementia

Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease

(2012) Henrik Zetterberg   ARCHIVES OF NEUROLOGY

Sustained levels of antibodies against Aβ in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic mice

(2012) Frédérique Bard et al.   EXPERIMENTAL NEUROLOGY

An Effector-Reduced Anti- -Amyloid (A ) Antibody with Unique A  Binding Properties Promotes Neuroprotection and Glial Engulfment of A 

(2012) O. Adolfsson et al.   JOURNAL OF NEUROSCIENCE

Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study

(2012) Bengt Winblad et al.   LANCET NEUROLOGY

PRINT - ALZHEIMER’S

(2012) Meredith Wadman   NATURE

A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline

(2012) Thorlakur Jonsson et al.   NATURE

Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease

(2012) Randall J. Bateman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Stopping Alzheimer's Before It Starts

(2012) G. Miller   SCIENCE

Using Positron Emission Tomography and Florbetapir F 18 to Image Cortical Amyloid in Patients With Mild Cognitive Impairment or Dementia Due to Alzheimer Disease

(2011) Adam S. Fleisher   ARCHIVES OF NEUROLOGY

DNA Immunization Against Amyloid beta 42 has High Potential as Safe Therapy for Alzheimer’s Disease as it Diminishes Antigen-Specific Th1 and Th17 Cell Proliferation

(2011) Doris Lambracht-Washington et al.   CELLULAR AND MOLECULAR NEUROBIOLOGY

Beneficial effect of human anti-amyloid-β active immunization on neurite morphology and tau pathology

(2010) Alberto Serrano-Pozo et al.   BRAIN

Analysis of three plasmid systems for use in DNA Aβ42 immunization as therapy for Alzheimer's disease

(2010) Bao-Xi Qu et al.   VACCINE

DNA prime–protein boost increased the titer, avidity and persistence of anti-Aβ antibodies in wild-type mice

(2009) H Davtyan et al.   GENE THERAPY

DNA β-Amyloid1-42 Trimer Immunization for Alzheimer Disease in a Wild-Type Mouse Model

(2009) Doris Lambracht-Washington   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Reduced oligomeric and vascular amyloid-β following immunization of TgCRND8 mice with an Alzheimer's DNA vaccine

(2009) Kevin A. DaSilva et al.   VACCINE

Vaccination of Alzheimer's model mice with adenovirus vector containing quadrivalent foldable Aβ1–15 reduces Aβ burden and behavioral impairment without Aβ-specific T cell response

(2008) Juntao Zou et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

(2008) Clive Holmes et al.   LANCET

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease

(2008) Norman R. Relkin et al.   NEUROBIOLOGY OF AGING

Enhanced Th2 immunity after DNA prime–protein boost immunization with amyloid β (1–42) plus CpG oligodeoxynucleotides in aged rats

(2008) Sarada Subramanian et al.   NEUROSCIENCE LETTERS

Reducing AD-Like Pathology in 3xTg-AD Mouse Model by DNA Epitope Vaccine — A Novel Immunotherapeutic Strategy

(2008) Nina Movsesyan et al.   PLoS One